$2.5 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 99 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PTXTQ | Exit | PERNIX THERAPEUTICS HLDGS IN | $0 | – | -658,826 | -100.0% | -0.02% | – |
| FOMX | Exit | FOAMIX PHARMACEUTICALS LTD | $0 | – | -234,745 | -100.0% | -0.05% | – |
| TLGT | Exit | TELIGENT INC NEW | $0 | – | -708,873 | -100.0% | -0.10% | – |
| ALBO | Exit | ALBIREO PHARMA INC | $0 | – | -120,000 | -100.0% | -0.14% | – |
| EIDX | Exit | EIDOS THERAPEUTICS INC | $0 | – | -420,409 | -100.0% | -0.15% | – |
| VKTX | Exit | VIKING THERAPEUTICS INC | $0 | – | -460,000 | -100.0% | -0.29% | – |
| QURE | Exit | UNIQURE NV | $0 | – | -241,430 | -100.0% | -0.32% | – |
| BLUE | Exit | BLUEBIRD BIO INC | $0 | – | -61,435 | -100.0% | -0.32% | – |
| BHVN | Exit | BIOHAVEN PHARMACTL HLDG CO L | $0 | – | -239,000 | -100.0% | -0.32% | – |
| ALLK | Exit | ALLAKOS INC | $0 | – | -225,000 | -100.0% | -0.36% | – |
| NITE | Exit | NIGHTSTAR THERAPEUTICS PLCadr | $0 | – | -499,747 | -100.0% | -0.37% | – |
| GTHX | Exit | G1 THERAPEUTICS INC | $0 | – | -287,000 | -100.0% | -0.54% | – |
| AIMT | Exit | AIMMUNE THERAPEUTICS INC | $0 | – | -553,000 | -100.0% | -0.54% | – |
| ZBH | Exit | ZIMMER BIOMET HLDGS INC | $0 | – | -121,000 | -100.0% | -0.57% | – |
| OXFD | Exit | OXFORD IMMUNOTEC GLOBAL PLC | $0 | – | -1,087,359 | -100.0% | -0.63% | – |
| EPZM | Exit | EPIZYME INC | $0 | – | -1,779,094 | -100.0% | -0.68% | – |
| RGNX | Exit | REGENXBIO INC | $0 | – | -275,000 | -100.0% | -0.74% | – |
| AGIO | Exit | AGIOS PHARMACEUTICALS INC | $0 | – | -348,200 | -100.0% | -0.96% | – |
| Exit | K2M GROUP HLDGS INCnote 4.125% 8/1 | $0 | – | -20,000,000 | -100.0% | -1.08% | – | |
| ECYT | Exit | ENDOCYTE INC | $0 | – | -3,514,084 | -100.0% | -2.24% | – |
| DBVT | Exit | DBV TECHNOLOGIES S Asponsored adr | $0 | – | -2,900,000 | -100.0% | -2.33% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-14 |
| 4 | 2024-06-03 |
| 13F-HR | 2024-05-15 |
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.